Effectiveness of neuraminidase inhibitors in preventing hospitalization during the H1N1 influenza pandemic in British Columbia, Canada.
Identifieur interne : 000295 ( Main/Exploration ); précédent : 000294; suivant : 000296Effectiveness of neuraminidase inhibitors in preventing hospitalization during the H1N1 influenza pandemic in British Columbia, Canada.
Auteurs : Fawziah Marra [Canada] ; Mei Chong ; Bonnie Henry ; David M. Patrick ; Perry KendallSource :
- The Journal of antimicrobial chemotherapy [ 1460-2091 ] ; 2014.
Descripteurs français
- KwdFr :
- Adolescent, Adulte, Adulte d'âge moyen, Antiviraux (usage thérapeutique), Colombie-Britannique, Enfant, Enfant d'âge préscolaire, Femelle, Grippe humaine (traitement médicamenteux), Hospitalisation (), Humains, Jeune adulte, Mâle, Nourrisson, Nouveau-né, Oséltamivir (usage thérapeutique), Résultat thérapeutique, Sialidase (antagonistes et inhibiteurs), Sous-type H1N1 du virus de la grippe A (), Sujet âgé, Sujet âgé de 80 ans ou plus, Zanamivir (usage thérapeutique), Études de cohortes, Études rétrospectives.
- MESH :
- antagonistes et inhibiteurs : Sialidase.
- traitement médicamenteux : Grippe humaine.
- usage thérapeutique : Antiviraux, Oséltamivir, Zanamivir.
- Adolescent, Adulte, Adulte d'âge moyen, Colombie-Britannique, Enfant, Enfant d'âge préscolaire, Femelle, Hospitalisation, Humains, Jeune adulte, Mâle, Nourrisson, Nouveau-né, Résultat thérapeutique, Sous-type H1N1 du virus de la grippe A, Sujet âgé, Sujet âgé de 80 ans ou plus, Études de cohortes, Études rétrospectives.
English descriptors
- KwdEn :
- Adolescent, Adult, Aged, Aged, 80 and over, Antiviral Agents (therapeutic use), British Columbia, Child, Child, Preschool, Cohort Studies, Female, Hospitalization (statistics & numerical data), Humans, Infant, Infant, Newborn, Influenza A Virus, H1N1 Subtype (drug effects), Influenza, Human (drug therapy), Male, Middle Aged, Neuraminidase (antagonists & inhibitors), Oseltamivir (therapeutic use), Retrospective Studies, Treatment Outcome, Young Adult, Zanamivir (therapeutic use).
- MESH :
- chemical , antagonists & inhibitors : Neuraminidase.
- chemical , therapeutic use : Antiviral Agents, Oseltamivir, Zanamivir.
- geographic : British Columbia.
- drug effects : Influenza A Virus, H1N1 Subtype.
- drug therapy : Influenza, Human.
- statistics & numerical data : Hospitalization.
- Adolescent, Adult, Aged, Aged, 80 and over, Child, Child, Preschool, Cohort Studies, Female, Humans, Infant, Infant, Newborn, Male, Middle Aged, Retrospective Studies, Treatment Outcome, Young Adult.
Abstract
OBJECTIVES
In British Columbia (BC), Canada, neuraminidase inhibitors (NIs) were publicly funded during the 2009 A(H1N1)pdm09 pandemic for treatment of high-risk patients and/or anyone with moderate-to-severe illness. We assessed antiviral effectiveness (AVE) against hospitalization in that context.
METHODS
A population-based cohort study was conducted using linked administrative data. The cohort included all individuals living in BC during the study period (1 September to 31 December 2009) with a diagnostic code consistent with influenza or pandemic H1N1. The main study period pertained to the second-wave A(H1N1)pdm09 circulation (1 October to 31 December 2009), with sensitivity analyses around the more specific pandemic peak (18 October to 7 November). Exposure was defined by same-day NI prescription. The main outcome was all-cause hospitalization within 14 days of the outpatient influenza diagnosis. Cox proportional hazards models assessed AVE with 1 : 1 propensity-score matching and covariate adjustment.
RESULTS
After matching, there were 304/58,061 NI-exposed and 345/58,061 unexposed patients hospitalized during the main study period. The very young [<6 months (35.0; 95% CI 16.7-73.4)], the old [65-79 years (13.7; 95% CI 10.1-18.6)] and the very old [≥80 years (38.7; 95% CI 26.6-56.5)] had the highest hospitalization rate per 1000 patients overall. Fully adjusted AVE against all-cause hospitalization during the main study period was 16% (95% CI 2%-28%), similar to the pandemic peak (15%; 95% CI -4%-30%).
CONCLUSIONS
The use of NIs was associated with modest protection against hospitalization during the 2009 pandemic, but appeared underutilized in affected age groups with the highest hospitalization risk.
DOI: 10.1093/jac/dkt496
PubMed: 24346762
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Effectiveness of neuraminidase inhibitors in preventing hospitalization during the H1N1 influenza pandemic in British Columbia, Canada.</title><author><name sortKey="Marra, Fawziah" sort="Marra, Fawziah" uniqKey="Marra F" first="Fawziah" last="Marra">Fawziah Marra</name><affiliation wicri:level="1"><nlm:affiliation>University of British Columbia, Vancouver, BC, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>University of British Columbia, Vancouver, BC</wicri:regionArea><wicri:noRegion>BC</wicri:noRegion></affiliation></author><author><name sortKey="Chong, Mei" sort="Chong, Mei" uniqKey="Chong M" first="Mei" last="Chong">Mei Chong</name></author><author><name sortKey="Henry, Bonnie" sort="Henry, Bonnie" uniqKey="Henry B" first="Bonnie" last="Henry">Bonnie Henry</name></author><author><name sortKey="Patrick, David M" sort="Patrick, David M" uniqKey="Patrick D" first="David M" last="Patrick">David M. Patrick</name></author><author><name sortKey="Kendall, Perry" sort="Kendall, Perry" uniqKey="Kendall P" first="Perry" last="Kendall">Perry Kendall</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2014">2014</date><idno type="RBID">pubmed:24346762</idno><idno type="pmid">24346762</idno><idno type="doi">10.1093/jac/dkt496</idno><idno type="wicri:Area/Main/Corpus">000307</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000307</idno><idno type="wicri:Area/Main/Curation">000307</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000307</idno><idno type="wicri:Area/Main/Exploration">000307</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Effectiveness of neuraminidase inhibitors in preventing hospitalization during the H1N1 influenza pandemic in British Columbia, Canada.</title><author><name sortKey="Marra, Fawziah" sort="Marra, Fawziah" uniqKey="Marra F" first="Fawziah" last="Marra">Fawziah Marra</name><affiliation wicri:level="1"><nlm:affiliation>University of British Columbia, Vancouver, BC, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>University of British Columbia, Vancouver, BC</wicri:regionArea><wicri:noRegion>BC</wicri:noRegion></affiliation></author><author><name sortKey="Chong, Mei" sort="Chong, Mei" uniqKey="Chong M" first="Mei" last="Chong">Mei Chong</name></author><author><name sortKey="Henry, Bonnie" sort="Henry, Bonnie" uniqKey="Henry B" first="Bonnie" last="Henry">Bonnie Henry</name></author><author><name sortKey="Patrick, David M" sort="Patrick, David M" uniqKey="Patrick D" first="David M" last="Patrick">David M. Patrick</name></author><author><name sortKey="Kendall, Perry" sort="Kendall, Perry" uniqKey="Kendall P" first="Perry" last="Kendall">Perry Kendall</name></author></analytic><series><title level="j">The Journal of antimicrobial chemotherapy</title><idno type="eISSN">1460-2091</idno><imprint><date when="2014" type="published">2014</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adolescent</term><term>Adult</term><term>Aged</term><term>Aged, 80 and over</term><term>Antiviral Agents (therapeutic use)</term><term>British Columbia</term><term>Child</term><term>Child, Preschool</term><term>Cohort Studies</term><term>Female</term><term>Hospitalization (statistics & numerical data)</term><term>Humans</term><term>Infant</term><term>Infant, Newborn</term><term>Influenza A Virus, H1N1 Subtype (drug effects)</term><term>Influenza, Human (drug therapy)</term><term>Male</term><term>Middle Aged</term><term>Neuraminidase (antagonists & inhibitors)</term><term>Oseltamivir (therapeutic use)</term><term>Retrospective Studies</term><term>Treatment Outcome</term><term>Young Adult</term><term>Zanamivir (therapeutic use)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adolescent</term><term>Adulte</term><term>Adulte d'âge moyen</term><term>Antiviraux (usage thérapeutique)</term><term>Colombie-Britannique</term><term>Enfant</term><term>Enfant d'âge préscolaire</term><term>Femelle</term><term>Grippe humaine (traitement médicamenteux)</term><term>Hospitalisation ()</term><term>Humains</term><term>Jeune adulte</term><term>Mâle</term><term>Nourrisson</term><term>Nouveau-né</term><term>Oséltamivir (usage thérapeutique)</term><term>Résultat thérapeutique</term><term>Sialidase (antagonistes et inhibiteurs)</term><term>Sous-type H1N1 du virus de la grippe A ()</term><term>Sujet âgé</term><term>Sujet âgé de 80 ans ou plus</term><term>Zanamivir (usage thérapeutique)</term><term>Études de cohortes</term><term>Études rétrospectives</term></keywords><keywords scheme="MESH" type="chemical" qualifier="antagonists & inhibitors" xml:lang="en"><term>Neuraminidase</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiviral Agents</term><term>Oseltamivir</term><term>Zanamivir</term></keywords><keywords scheme="MESH" type="geographic" xml:lang="en"><term>British Columbia</term></keywords><keywords scheme="MESH" qualifier="antagonistes et inhibiteurs" xml:lang="fr"><term>Sialidase</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Influenza A Virus, H1N1 Subtype</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Influenza, Human</term></keywords><keywords scheme="MESH" qualifier="statistics & numerical data" xml:lang="en"><term>Hospitalization</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Grippe humaine</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Antiviraux</term><term>Oséltamivir</term><term>Zanamivir</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adolescent</term><term>Adult</term><term>Aged</term><term>Aged, 80 and over</term><term>Child</term><term>Child, Preschool</term><term>Cohort Studies</term><term>Female</term><term>Humans</term><term>Infant</term><term>Infant, Newborn</term><term>Male</term><term>Middle Aged</term><term>Retrospective Studies</term><term>Treatment Outcome</term><term>Young Adult</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adolescent</term><term>Adulte</term><term>Adulte d'âge moyen</term><term>Colombie-Britannique</term><term>Enfant</term><term>Enfant d'âge préscolaire</term><term>Femelle</term><term>Hospitalisation</term><term>Humains</term><term>Jeune adulte</term><term>Mâle</term><term>Nourrisson</term><term>Nouveau-né</term><term>Résultat thérapeutique</term><term>Sous-type H1N1 du virus de la grippe A</term><term>Sujet âgé</term><term>Sujet âgé de 80 ans ou plus</term><term>Études de cohortes</term><term>Études rétrospectives</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p><b>OBJECTIVES</b></p><p>In British Columbia (BC), Canada, neuraminidase inhibitors (NIs) were publicly funded during the 2009 A(H1N1)pdm09 pandemic for treatment of high-risk patients and/or anyone with moderate-to-severe illness. We assessed antiviral effectiveness (AVE) against hospitalization in that context.</p></div><div type="abstract" xml:lang="en"><p><b>METHODS</b></p><p>A population-based cohort study was conducted using linked administrative data. The cohort included all individuals living in BC during the study period (1 September to 31 December 2009) with a diagnostic code consistent with influenza or pandemic H1N1. The main study period pertained to the second-wave A(H1N1)pdm09 circulation (1 October to 31 December 2009), with sensitivity analyses around the more specific pandemic peak (18 October to 7 November). Exposure was defined by same-day NI prescription. The main outcome was all-cause hospitalization within 14 days of the outpatient influenza diagnosis. Cox proportional hazards models assessed AVE with 1 : 1 propensity-score matching and covariate adjustment.</p></div><div type="abstract" xml:lang="en"><p><b>RESULTS</b></p><p>After matching, there were 304/58,061 NI-exposed and 345/58,061 unexposed patients hospitalized during the main study period. The very young [<6 months (35.0; 95% CI 16.7-73.4)], the old [65-79 years (13.7; 95% CI 10.1-18.6)] and the very old [≥80 years (38.7; 95% CI 26.6-56.5)] had the highest hospitalization rate per 1000 patients overall. Fully adjusted AVE against all-cause hospitalization during the main study period was 16% (95% CI 2%-28%), similar to the pandemic peak (15%; 95% CI -4%-30%).</p></div><div type="abstract" xml:lang="en"><p><b>CONCLUSIONS</b></p><p>The use of NIs was associated with modest protection against hospitalization during the 2009 pandemic, but appeared underutilized in affected age groups with the highest hospitalization risk.</p></div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">24346762</PMID><DateCompleted><Year>2014</Year><Month>11</Month><Day>24</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1460-2091</ISSN><JournalIssue CitedMedium="Internet"><Volume>69</Volume><Issue>5</Issue><PubDate><Year>2014</Year><Month>May</Month></PubDate></JournalIssue><Title>The Journal of antimicrobial chemotherapy</Title><ISOAbbreviation>J. Antimicrob. Chemother.</ISOAbbreviation></Journal><ArticleTitle>Effectiveness of neuraminidase inhibitors in preventing hospitalization during the H1N1 influenza pandemic in British Columbia, Canada.</ArticleTitle><Pagination><MedlinePgn>1397-406</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1093/jac/dkt496</ELocationID><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">In British Columbia (BC), Canada, neuraminidase inhibitors (NIs) were publicly funded during the 2009 A(H1N1)pdm09 pandemic for treatment of high-risk patients and/or anyone with moderate-to-severe illness. We assessed antiviral effectiveness (AVE) against hospitalization in that context.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A population-based cohort study was conducted using linked administrative data. The cohort included all individuals living in BC during the study period (1 September to 31 December 2009) with a diagnostic code consistent with influenza or pandemic H1N1. The main study period pertained to the second-wave A(H1N1)pdm09 circulation (1 October to 31 December 2009), with sensitivity analyses around the more specific pandemic peak (18 October to 7 November). Exposure was defined by same-day NI prescription. The main outcome was all-cause hospitalization within 14 days of the outpatient influenza diagnosis. Cox proportional hazards models assessed AVE with 1 : 1 propensity-score matching and covariate adjustment.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">After matching, there were 304/58,061 NI-exposed and 345/58,061 unexposed patients hospitalized during the main study period. The very young [<6 months (35.0; 95% CI 16.7-73.4)], the old [65-79 years (13.7; 95% CI 10.1-18.6)] and the very old [≥80 years (38.7; 95% CI 26.6-56.5)] had the highest hospitalization rate per 1000 patients overall. Fully adjusted AVE against all-cause hospitalization during the main study period was 16% (95% CI 2%-28%), similar to the pandemic peak (15%; 95% CI -4%-30%).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The use of NIs was associated with modest protection against hospitalization during the 2009 pandemic, but appeared underutilized in affected age groups with the highest hospitalization risk.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Marra</LastName><ForeName>Fawziah</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>University of British Columbia, Vancouver, BC, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chong</LastName><ForeName>Mei</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Henry</LastName><ForeName>Bonnie</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Patrick</LastName><ForeName>David M</ForeName><Initials>DM</Initials></Author><Author ValidYN="Y"><LastName>Kendall</LastName><ForeName>Perry</ForeName><Initials>P</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2013</Year><Month>12</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Antimicrob Chemother</MedlineTA><NlmUniqueID>7513617</NlmUniqueID><ISSNLinking>0305-7453</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>20O93L6F9H</RegistryNumber><NameOfSubstance UI="D053139">Oseltamivir</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.2.1.18</RegistryNumber><NameOfSubstance UI="D009439">Neuraminidase</NameOfSubstance></Chemical><Chemical><RegistryNumber>L6O3XI777I</RegistryNumber><NameOfSubstance UI="D053243">Zanamivir</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001955" MajorTopicYN="N" Type="Geographic">British Columbia</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006760" MajorTopicYN="N">Hospitalization</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics & numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007223" MajorTopicYN="N">Infant</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007231" MajorTopicYN="N">Infant, Newborn</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053118" MajorTopicYN="N">Influenza A Virus, H1N1 Subtype</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007251" MajorTopicYN="N">Influenza, Human</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009439" MajorTopicYN="N">Neuraminidase</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="Y">antagonists & inhibitors</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053139" MajorTopicYN="N">Oseltamivir</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053243" MajorTopicYN="N">Zanamivir</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">antivirals</Keyword><Keyword MajorTopicYN="N">cohort</Keyword><Keyword MajorTopicYN="N">mortality</Keyword><Keyword MajorTopicYN="N">oseltamivir</Keyword><Keyword MajorTopicYN="N">population-based</Keyword><Keyword MajorTopicYN="N">zanamivir</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>12</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>12</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>12</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24346762</ArticleId><ArticleId IdType="pii">dkt496</ArticleId><ArticleId IdType="doi">10.1093/jac/dkt496</ArticleId><ArticleId IdType="pmc">PMC3977606</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Med J Aust. 2010 May 17;192(10):617-22</Citation><ArticleIdList><ArticleId IdType="pubmed">20477746</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA. 2010 Apr 21;303(15):1517-25</Citation><ArticleIdList><ArticleId IdType="pubmed">20407061</ArticleId></ArticleIdList></Reference><Reference><Citation>Health Technol Assess. 2010 Jul;14(34):109-82</Citation><ArticleIdList><ArticleId IdType="pubmed">20630123</ArticleId></ArticleIdList></Reference><Reference><Citation>Pediatr Crit Care Med. 2010 Sep;11(5):603-9</Citation><ArticleIdList><ArticleId IdType="pubmed">20308929</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Infect Dis. 2011 Feb 1;52(3):301-12</Citation><ArticleIdList><ArticleId IdType="pubmed">21208911</ArticleId></ArticleIdList></Reference><Reference><Citation>BMJ. 2011;342:c7297</Citation><ArticleIdList><ArticleId IdType="pubmed">21292718</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Infect Dis. 2011 Jan 1;52 Suppl 1:S50-9</Citation><ArticleIdList><ArticleId IdType="pubmed">21342900</ArticleId></ArticleIdList></Reference><Reference><Citation>J Antimicrob Chemother. 2011 May;66(5):1150-5</Citation><ArticleIdList><ArticleId IdType="pubmed">21393197</ArticleId></ArticleIdList></Reference><Reference><Citation>Influenza Other Respir Viruses. 2011 Jul;5(4):247-55</Citation><ArticleIdList><ArticleId IdType="pubmed">21651735</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS Med. 2011 Jul;8(7):e1001053</Citation><ArticleIdList><ArticleId IdType="pubmed">21750667</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet Infect Dis. 2012 Mar;12(3):240-8</Citation><ArticleIdList><ArticleId IdType="pubmed">22186145</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA. 2000 Feb 23;283(8):1016-24</Citation><ArticleIdList><ArticleId IdType="pubmed">10697061</ArticleId></ArticleIdList></Reference><Reference><Citation>J Infect. 2000 Jan;40(1):42-8</Citation><ArticleIdList><ArticleId IdType="pubmed">10762110</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2000 May 27;355(9218):1845-50</Citation><ArticleIdList><ArticleId IdType="pubmed">10866439</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Intern Med. 2001 Jan 22;161(2):212-7</Citation><ArticleIdList><ArticleId IdType="pubmed">11176734</ArticleId></ArticleIdList></Reference><Reference><Citation>Pediatr Infect Dis J. 2001 Feb;20(2):127-33</Citation><ArticleIdList><ArticleId IdType="pubmed">11224828</ArticleId></ArticleIdList></Reference><Reference><Citation>J Antimicrob Chemother. 2003 Jan;51(1):123-9</Citation><ArticleIdList><ArticleId IdType="pubmed">12493796</ArticleId></ArticleIdList></Reference><Reference><Citation>BMJ. 2003 Jun 7;326(7401):1235</Citation><ArticleIdList><ArticleId IdType="pubmed">12791735</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Intern Med. 2003 Jul 28;163(14):1667-72</Citation><ArticleIdList><ArticleId IdType="pubmed">12885681</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 1997 Sep 25;337(13):874-80</Citation><ArticleIdList><ArticleId IdType="pubmed">9302301</ArticleId></ArticleIdList></Reference><Reference><Citation>J Infect Dis. 1999 Aug;180(2):254-61</Citation><ArticleIdList><ArticleId IdType="pubmed">10395837</ArticleId></ArticleIdList></Reference><Reference><Citation>Med Care. 2005 Nov;43(11):1130-9</Citation><ArticleIdList><ArticleId IdType="pubmed">16224307</ArticleId></ArticleIdList></Reference><Reference><Citation>MMWR Morb Mortal Wkly Rep. 2009 Apr 24;58(15):400-2</Citation><ArticleIdList><ArticleId IdType="pubmed">19390508</ArticleId></ArticleIdList></Reference><Reference><Citation>MMWR Morb Mortal Wkly Rep. 2009 May 1;58(16):431-3</Citation><ArticleIdList><ArticleId IdType="pubmed">19407737</ArticleId></ArticleIdList></Reference><Reference><Citation>MMWR Morb Mortal Wkly Rep. 2009 May 8;58(17):467-70</Citation><ArticleIdList><ArticleId IdType="pubmed">19444150</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2009 Jul 9;361(2):212-4</Citation><ArticleIdList><ArticleId IdType="pubmed">19564630</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2009 Aug 8;374(9688):451-8</Citation><ArticleIdList><ArticleId IdType="pubmed">19643469</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2009 Aug 22;374(9690):605-7</Citation><ArticleIdList><ArticleId IdType="pubmed">19700000</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA. 2009 Nov 4;302(17):1872-9</Citation><ArticleIdList><ArticleId IdType="pubmed">19822627</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA. 2009 Nov 4;302(17):1896-902</Citation><ArticleIdList><ArticleId IdType="pubmed">19887665</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2009 Nov 12;361(20):1935-44</Citation><ArticleIdList><ArticleId IdType="pubmed">19815859</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2009 Nov 12;361(20):1925-34</Citation><ArticleIdList><ArticleId IdType="pubmed">19815860</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2009 Dec 31;361(27):2628-36</Citation><ArticleIdList><ArticleId IdType="pubmed">20042754</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2010 Jan 7;362(1):27-35</Citation><ArticleIdList><ArticleId IdType="pubmed">20032319</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2010 Jan 7;362(1):45-55</Citation><ArticleIdList><ArticleId IdType="pubmed">20032320</ArticleId></ArticleIdList></Reference><Reference><Citation>BMJ. 2010;340:c1279</Citation><ArticleIdList><ArticleId IdType="pubmed">20299694</ArticleId></ArticleIdList></Reference><Reference><Citation>Obstet Gynecol. 2010 Apr;115(4):717-26</Citation><ArticleIdList><ArticleId IdType="pubmed">20308830</ArticleId></ArticleIdList></Reference><Reference><Citation>Chest. 2010 Apr;137(4):752-8</Citation><ArticleIdList><ArticleId IdType="pubmed">19933372</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS One. 2010;5(5):e10896</Citation><ArticleIdList><ArticleId IdType="pubmed">20531946</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed><affiliations><list><country><li>Canada</li></country></list><tree><noCountry><name sortKey="Chong, Mei" sort="Chong, Mei" uniqKey="Chong M" first="Mei" last="Chong">Mei Chong</name><name sortKey="Henry, Bonnie" sort="Henry, Bonnie" uniqKey="Henry B" first="Bonnie" last="Henry">Bonnie Henry</name><name sortKey="Kendall, Perry" sort="Kendall, Perry" uniqKey="Kendall P" first="Perry" last="Kendall">Perry Kendall</name><name sortKey="Patrick, David M" sort="Patrick, David M" uniqKey="Patrick D" first="David M" last="Patrick">David M. Patrick</name></noCountry><country name="Canada"><noRegion><name sortKey="Marra, Fawziah" sort="Marra, Fawziah" uniqKey="Marra F" first="Fawziah" last="Marra">Fawziah Marra</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/GrippeCanadaV3/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000295 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000295 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= GrippeCanadaV3
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:24346762
|texte= Effectiveness of neuraminidase inhibitors in preventing hospitalization during the H1N1 influenza pandemic in British Columbia, Canada.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:24346762" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a GrippeCanadaV3
| This area was generated with Dilib version V0.6.35. |  |